Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IBI343 + sintilimab in CLDN18.2-positive advanced gastric or gastroesophageal junction adenocarcinoma
ChiCTR2300077564Phase 2Not yet recruiting
- Sponsor
- First Affiliated Hospital of Anhui Medical University
- Start
- Nov 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of arcotatug tavatecan and sintilimab in gastric adenocarcinoma and gastroesophageal junction adenocarcinoma, sponsored by First Affiliated Hospital of Anhui Medical University. Primary endpoints: Objective response rate, Adverse events and 3 more. Planned start Nov 2023; status: not yet recruiting.
02
Drugs
arcotatug tavatecansintilimab
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on ChiCTR2300077564.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300077564.